Myeloid-derived growth factor attenuates hepatic ischemia-reperfusion injury by targeting TWEAK/TNFRSF12A
Hepatic IRI mouse models of C57/BL6 mice were established for 90 min and mice were treated with MYDGF via intraperitoneal injection. Mice were sacrificed 1 day after IRI, and livers were collected. mRNA sequencing and bioinformatics predicted the mechanism of the therapeutic effect of MYDGF.